Less Invasive Treatment May Increase Survival In Early Stage Breast Cancer

Source : Duke University Medical Center

DURHAM, N.C. -- Patients with early stage breast cancer who are treated with lumpectomy plus radiation have a better chance of survival compared with those who undergo mastectomy, according to Duke Medicine research.

The study, which appears online Jan. 28, 2013, in the journal CANCER, demonstrates the effectiveness of breast-conserving therapies such as lumpectomy, where only the tumor and surrounding tissue are surgically removed.

"Our findings support the notion that less invasive treatment can provide superior survival to mastectomy in stage I or stage II breast cancer," said E. Shelley Hwang, M.D., MPH, chief of breast surgery at Duke Cancer Institute and the study's lead author.

Using 14 years of data from the California Cancer Registry, a source of long-term outcome data for cancer, the research team found improved survival to be associated with the less invasive treatment in all age groups, as well as those with both hormone-sensitive and hormone-resistant cancers. Women age 50 and older at diagnosis with hormone-sensitive tumors saw the largest benefit of choosing lumpectomy plus radiation: they were 13 percent less likely to die from breast cancer, and 19 percent less likely to die from any cause compared with those undergoing mastectomy.

Prior research has shown that lumpectomy with radiation is as effective as mastectomy in treating early stage breast cancer. As a result, the rate of women electing lumpectomy with radiation has climbed in the past few decades.

However, a recent trend has emerged with some early stage breast cancer patients, often younger women, opting for mastectomy. These women may perceive mastectomy to be more effective at eliminating early stage cancer and therefore reducing the anxiety accompanying long-term surveillance.

"Given the recent interest in mastectomy to treat early stage breast cancers, despite the research supporting lumpectomy, our study sought to further explore outcomes of breast-conserving treatments in the general population comparing outcomes between younger and older women," Hwang said.

The team analyzed data from 112,154 women diagnosed with stage I or stage II breast cancer between 1990 and 2004, including 61,771 who received lumpectomy and radiation and 50,383 who had mastectomy without radiation. They looked at age and other demographic factors, along with tumor type and size to decipher whether each treatment had better outcomes for certain groups of women. Patients were followed on average for 9.2 years.

The researchers evaluated whether illnesses other than breast cancer, such as heart and respiratory disease, may have influenced whether women chose lumpectomy or mastectomy. Within three years of diagnosis, breast cancer patients who underwent lumpectomy and radiation had higher survival rates than those who chose mastectomy when all other illnesses were evaluated. This suggests that women choosing lumpectomy may have been generally healthier.

Hwang and her colleagues were surprised to also find that early stage breast cancer patients treated with mastectomy had a significantly lower survival rate from breast cancer than women who underwent lumpectomy with radiation.

"We found that lumpectomy plus radiation was an effective alternative to mastectomy for early stage disease, regardless of age or tumor type," said Hwang. "Even patients we thought might benefit less from localized treatment, like younger patients with hormone-resistant disease, can remain confident in lumpectomy as an equivalent and possibly better treatment option."

  • <<
  • >>

Articles List

  • Planting a Seed for CRISPR/Cas9 Genome Editing

    Planting a Seed for CRISPR/Cas9 Genome Editing

    The recent discovery and development of the CRISPR/Cas9 system for genome editing has transformed the molecular-biology landscape. The technology allows researchers to knock out or alter gene sequences in live organisms efficiently with a bacterial nuclease (Cas9) and a short guide RNA to direct the nuclease where to cut. The CRISPR/Cas9 system originated in bacteria, where it serves as a form of adaptive immunity. But it works in a range of organisms, from primates to pathogens, enabling researchers to engineer genomes even in organisms that have less well-established genetic toolsets than mice and man—including plants [1, 2]. A 2014 review detailed that “[most] studies to date have been conducted in animal systems, but CRISPR/Cas9-mediated mutagenesis was recently demonstrated in Arabidopsis, tobacco, sorghum, rice and wheat, proving that this technique is applicable to both dicot and monocot plants” [1]. Here’s what you need to know when considering whether to use this powerful technology on plant systems.
  • Choosing Serum for Cells in Culture

    Choosing Serum for Cells in Culture

    Serum is a key component for growing and maintaining cells in culture. Containing a mixture of proteins, hormones, minerals and other growth factors, serum is a nutrient boost for cultured cells. It is added to media as a growth supplement, and specialized forms can be used for different experimental conditions. Determining the serum conditions that provide optimal cell growth can be a challenging task. “Selection of sera products is dependent upon the growth requirements of the cell type it’s being used for, with sensitive cell lines often requiring the highest quality serum,” says Brian Douglass, global head of cell-culture product management and marketing in life sciences at GE Healthcare. Many suppliers offer serum, in various formulations and with different purity levels. Fetal bovine serum (FBS), or fetal calf serum (FCS), is the most widely used form, but there are features and options to consider. Here we discuss some key considerations when selecting sera for culturing cells.

Disqus Comments